EpiCept seeks M&A or partners for PhIII-ready AmiKet for chemotherapy-induced neuropathic pain
This article was originally published in Scrip
Executive Summary
EpiCept, a US company with one oncology product, Ceplene (histamine dihydrochloride), approved in Europe but not in the US, has a liquidity problem and recurring losses, and now has confirmed that it has engaged investment bank SunTrust Robinson Humphrey to explore options, including a possible sale of the company.